Mapping Disease Pathways for Biliary Atresia
ConditionBiliary Atresia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity of Pittsburgh
About this trial
This project will primarily evaluate the developmental/genetic basis of biliary atresia, the most common cause of liver failure at birth, and which accounts of half of all liver transplants performed worldwide in children.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
living individuals who were diagnosed with Biliary Atresia and received or are about to receive a liver transplant from multiple participating centers (Children's Hospital of Pittsburgh, Kings College Hospital, Children's Hospital of Birmingham, and Hospital Sírio-Libanês).
Disqualifiers
No child participant in the care of the state will be enrolled, nor will patients in the care of temporary or informal guardians be enrolled
Trial population
Individuals who have had a liver transplantation due to a diagnosis of biliary atresia.
Trial design
Design model
Other
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Genomic pathways of BA
Main project outcome will consist of pathways comprising multiple susceptibility genes involved in morphogenesis of the liver and other organs, which explain the complex phenotype of BA.
Time frame
up to two yearsSecondary outcomes
1
Predisposition of BA
determine whether candidate genes and related pathways which predispose to BA, also predispose to laterality defects affecting the liver and other organs.
Time frame
upwards of four years to achieve this outcome measureSponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Pittsburgh
Lead sponsor
National Institutes of Health (NIH)
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Source ClinicalTrials.gov